In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $40.4, along with a high estimate of $45.00 and a low estimate of $39.00. Highlighting a 25.64% decrease, the current average has fallen from the previous average price target of $54.33.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of...
Login or create a forever free account to read this news
Sign up/Log in